Top Ten most popular articles on Pharmafile.com this week
pharmafile | February 2, 2018 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing |Â Â Ablynx, Alzheimer's, Apotex, AstraZeneca, Brexit Health Alliance, CDC, Duchenne Muscular Dystrophy, EMA, Italy, Sanofi, amazon, brexit, santhera, top tenÂ
It’s the first Friday of February, and it’s time for another recap of the top ten articles most popular with our readers this week.
The United States’ most foremost public health body, the Centers for Disease Control and Prevention, was shaken this week with the news that its Director has resigned after being discovered to have purchased stocks in big tobacco. And that’s not the only resignation this week, after Apotex President and CEO Jeremy Desai leaves amidst allegations he accepted company secrets from Teva – just a month after the company’s founder was found murdered.
Sanofi also made its second major acquisition of the year so far, buying out Ablynx for $4.8 billion, but the most popular story this week was the first tangible news of retail giant Amazon’s much-talked-about foray into the healthcare industry.
Check out the week’s ten most popular articles on Pharmafile.com now!
10. Brexit Health Alliance warns of UK at back of the medicine queue
The Brexit Health Alliance has cautioned that unless a favourable deal is struck, the UK could end Brexit negotiations as a comparatively small patient population in a global market – putting the country to the back of the queue in bringing new medicines to its shores.
9. CDC Director resigns over tobacco stock scandal
Dr Brenda Fitzgerald, the Director of the Centers for Disease Control and Prevention, the United States’ leading national public health institute, has resigned from her post amidst controversy surrounding financial conflicts of interest.
8. New blood test for Alzheimer’s offers hope
A new test is able to use a small amount of blood to determine, with 90% accuracy, whether a patient had a build of amyloid protein in the brain.
7. Santhera’s Raxone rejected in Europe for Duchenne muscular dystrophy
Santhera’s Raxone was left out of a recent raft of positive recommendations, rejected by an EMA advisory panel and given a negative opinion in the treatment of Duchenne muscular dystrophy (DMD).
6. Apotex President resigns amidst Founder’s murder and allegations of accepting Teva secrets
Canada’s largest generic drug producer Apotex has now lost its President and CEO, as Jeremy Desai resigns effective immediately, to “pursue other opportunities.
5. AZ’s triple therapy inhaler hits 8 out of 9 endpoints
AstraZeneca has made a brief announcement that its triple therapy inhaler manage to successfully hit eight of nine primary endpoints in the treatment of moderate to very severe chronic obstructive pulmonary disease.
4. EMA committee recommends seven therapies from Roche, GSK, MSD and more
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has voiced its recommendation of a raft of products in a number of therapeutic areas, including candidates from GlaxoSmithKline, Roche and MSD.
3. Sanofi swoops for Ablynx in $4.8bn deal
Sanofi has moved quickly to tie up a deal with Ablynx for $4.8 billion, when it looked more likely that Novo Nordisk would wear down the biotech’s resistance with repeated bids.
2. Italy refuses to give up hope on EMA HQ
It is no secret that Milan was not best pleased that it was pipped to the post to host the EMA headquarters by Amsterdam, and now it is attempting to get the decision revoked.
1. Amazon makes first steps into healthcare, alongside big partners
Amazon’s move into the healthcare sector has been widely mooted over the last 12 months and it officially announced that it would enter the space as part of a joint venture alongside Berkshire Hathaway and JPMorgan Chase.
Related Content
Rethinking oncology trial endpoints with generalised pairwise comparisons
For decades, oncology trials have been anchored to a familiar set of endpoints. Overall survival …
Sanofi and Regeneron’s Dupixent receives CHMP recommendation for chronic spontaneous urticaria
Sanofi and Regeneron have received a positive opinion from the European Medicines Agency’s (EMA) Committee …
NICE recommends Benralizumab for Rare Form of Vasculitis
The National Institute for Health and Care Excellence (NICE) has recommended AstraZeneca’s benralizumab (Fasenra) as …
